CORONADO, Calif. (EGMN) - Smokers with metastatic non-small cell lung cancer were able to tolerate much higher doses of the targeted therapy erlotinib than were their nonsmoking counterparts in a small, ongoing phase II clinical trial.The median maximum tolerated dose (MTD) of erlotinib (Tarceva) was 33% (75 mg) higher for patients who smoked, investigators reported at a joint conference of the American Association for Cancer Research and the International Association for the Study of Lung Cancer."Recent...